The STK11 gene (also called LKB1) provides instructions for making an enzyme called serine/threonine kinase 11. This enzyme is a tumor suppressor, which means that it helps keep cells from growing and dividing too fast or in an uncontrolled way.

2024年12月25日 · STK11 (Serine/Threonine Kinase 11) is a Protein Coding gene. Diseases associated with STK11 include Peutz-Jeghers Syndrome and Testicular Germ Cell Tumor. Among its related pathways are Gene expression (Transcription) and Regulation of TP53 Activity.

2022年8月12日 · STK11, also sometimes known as LKB1, is a gene that tells your body to make an enzyme called serine/threonine kinase 11. People who have a change, or mutation, in their STK11 gene, develop...

What is the STK11 mutation? Errors in the STK11 gene are one type of lung cancer biomarker. Mutations in the STK11 gene (also called LKB1) inactivate the STK11 protein. This leads to uncontrolled cell growth, which can cause cancer. Who is most likely to have a STK11 mutation?

STK11 overexpression prevents glucocorticoid-induced osteoporosis via activating the AMPK/SIRT1/PGC1alpha axis. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications.

2024年9月6日 · An inherited STK11 (Peutz-Jeghers Syndrome) mutation may affect your options for cancer prevention, detection and treatment. FORCE is here to guide you.

STK11 is a tumor suppressor gene that encodes for an enzyme called serine/threonine kinase 11 which is involved in AMPK pathway and regulates cell polarity. You might find these chapters and articles relevant to this topic. STK11 is known to be located both in the nucleus and the cytoplasm of all human tissues.

2022年1月29日 · STK11 mutation recently have become a biomarker and potential target of interest, especially for patients with lung cancer. Recent trials explore drugs like bemcentinib, everolimus, talazoparib, and others for potential approaches to targeting these mutations.

The STK11 mutation defines a special subtype of lung adenocarcinoma (LUAD) patients, and emerging evidences suggested that STK11 alterations may be prognostic and/or predictive of therapeutic response, particularly in immune- and targeted therapy, and some studies demonstrated that loss of function caused by STK11 mutation was highly correlated ...

STK11/LKB1-mutant lung cancers are currently treated with radiotherapy with or without chemotherapy. Recent clinical trials studying the effects of glutaminase inhibitors, mTOR inhibitors, and anti-PD-L1 therapy in lung cancer patients have yielded promising results.